Effects of insulin-mimetic vanadyl-poly(gamma-glutamic acid) complex on diabetic rat model

J Pharm Sci. 2010 Jul;99(7):3041-7. doi: 10.1002/jps.22071.

Abstract

Poly-gamma-glutamic acid (gamma-PGA) prepared by fermentation of microbe was used as drug carrier for vanadium sulfate to obtain vanadyl-poly-gamma-glutamic acid (VO-gamma-PGA) complex. The FI-IR spectrum of the complex demonstrated that the expected VO-gamma-PGA complex is formed by the coordination of VO(2+) through the side chain carboxylic groups of the gamma-PGA. Studies of the complex in treating type I diabetes were carried out on alloxan induced diabetes rats. The results of treating the rats in 2 weeks and then stopping administration for 10 days showed that VO-gamma-PGA can effectively lower blood glucose levels of diabetic rats during administration. But after ceasing treatment there were no differences between groups in blood glucose level and water intake. The results of oral glucose tolerance and some serum parameters also demonstrated that VO-gamma-PGA was more effective than vanadium sulfate in treating diabetic rats.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alloxan
  • Animals
  • Blood Glucose / drug effects
  • Diabetes Mellitus / chemically induced
  • Diabetes Mellitus / drug therapy*
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / chemistry
  • Hypoglycemic Agents / therapeutic use*
  • Male
  • Polyglutamic Acid / administration & dosage
  • Polyglutamic Acid / chemistry
  • Polyglutamic Acid / therapeutic use*
  • Rats
  • Vanadates / administration & dosage
  • Vanadates / chemistry
  • Vanadates / therapeutic use*
  • Vanadium / therapeutic use

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • vanadyl-poly (gamma-glutamic acid)
  • Vanadium
  • Polyglutamic Acid
  • Vanadates
  • Alloxan